[CLSTR]
< Back to situation

[REVISION HISTORY]

STAREE trial and evolving cholesterol treatments

Updated 4 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-11 11:12 UTC → 2026-09-12 09:43 UTC · added removed

STAREE trial statin efficacy in older adults and evolving cholesterol treatments

The STAREE trial, a large-scale clinical study involving nearly 10,000 participants from Australian general practices, has demonstrated that daily atorvastatin significantly reduces the risk of major cardiovascular events in healthy adults aged 70 and older. Findings published in the New England Journal of Medicine indicate a 30 per cent reduction in the risk of cardiovascular death, nonfatal myocardial infarction, stroke, and coronary revascularization among participants with no prior history of cardiovascular disease, diabetes, or dementia. The research addresses In absolute terms, this represented a historical evidence gap, as older populations were often underrepresented in previous studies that focused on middle-aged individuals or those who had already experienced reduction of approximately 2 to 3 events per 100 people treated over a cardiac event. median follow-up of 5.9 years. While the medication successfully lowered cardiovascular risks, researchers noted that it did not significantly improve mortality, dementia, or disability-free survival—defined as survival free survival. Recent research has also expanded the understanding of dementia cholesterol management. While statins inhibit cholesterol synthesis, studies into PCSK9 inhibitors, such as evolocumab and physical disability—over alirocumab, highlight their role in treating severe hypercholesterolemia. These inhibitors work by blocking a median follow-up of 5.9 years. The study also appears liver-produced protein, increasing the liver’s ability to address concerns regarding a potential link between statin use and dementia. Recent research remove LDL cholesterol from the bloodstream, offering an alternative for patients unable to reach therapeutic targets through statins alone. Additionally, scientists at the University of British Columbia and the University of Wisconsin–Madison has provided new insights into the side effects associated with this class of drugs. Using cryo-electron microscopy, scientists have identified a potential biological cause for statin-induced muscle pain, discovering pain. Using cryo-electron microscopy, they discovered that statins may attach to the RyR1 protein. This interaction can disrupt protein, disrupting calcium levels necessary for muscle contraction and relaxation. function. This finding aligns with observations from the STAREE trial, where musculoskeletal issues were noted to be slightly more frequent in the atorvastatin group than in the placebo group.

Versions

  1. 2026-09-12 09:43 UTC STAREE trial and evolving cholesterol treatments
  2. 2026-09-11 11:12 UTC STAREE trial statin efficacy in older adults
  3. 2026-09-04 12:51 UTC STAREE trial statin efficacy in older adults
  4. 2026-09-02 19:32 UTC STAREE trial statin efficacy in older adults
  5. 2026-08-29 20:13 UTC STAREE trial statin efficacy in older adults

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.